Q1 EPS Estimate for Jazz Pharmaceuticals Boosted by Analyst

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Research analysts at Zacks Research raised their Q1 2025 earnings per share estimates for Jazz Pharmaceuticals in a report released on Tuesday, March 18th. Zacks Research analyst S. Ganoria now anticipates that the specialty pharmaceutical company will post earnings of $3.51 per share for the quarter, up from their prior forecast of $3.17. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q2 2025 earnings at $4.70 EPS, Q3 2025 earnings at $5.30 EPS, Q4 2025 earnings at $5.51 EPS, FY2025 earnings at $19.02 EPS, Q1 2026 earnings at $3.13 EPS, Q2 2026 earnings at $4.79 EPS, Q3 2026 earnings at $5.84 EPS, Q4 2026 earnings at $5.90 EPS, FY2026 earnings at $19.66 EPS and FY2027 earnings at $20.50 EPS.

Other equities research analysts also recently issued research reports about the company. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Truist Financial lifted their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Royal Bank of Canada reduced their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $187.71.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $138.76 on Friday. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $8.43 billion, a P/E ratio of 19.54, a P/E/G ratio of 1.04 and a beta of 0.44. The stock’s fifty day moving average is $131.41 and its two-hundred day moving average is $121.61.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at $4,826,778.66. The trade was a 10.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now directly owns 439,744 shares of the company’s stock, valued at $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock valued at $4,022,825 in the last three months. 4.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. IFP Advisors Inc purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $25,000. Quadrant Capital Group LLC lifted its holdings in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the last quarter. Elequin Capital LP lifted its holdings in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares during the last quarter. CoreFirst Bank & Trust purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $28,000. Finally, Allianz SE purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $29,000. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.